



# Updates in Adult Immunization Schedule 2020

**Current Issues in Immunization Net Conference**

**March 18, 2020**

Mark Freedman, DVM, MPH

# Disclosure and Disclaimer

- The presenter has no conflict of interest
- The use of trade names is for identification purposes only and does not imply endorsement by CDC or ACIP
- Discussions on unlicensed products and off-label uses are in the context of ACIP recommendations
- The opinions expressed in this presentation are those of the presenter and do not necessarily represent official positions of CDC or ACIP

# Overview

- Background
- ACIP policy updates
- Harmonization with child and adolescent immunization schedule
- Changes in the 2020 adult immunization schedule

# Adult Immunization Schedule – Background

- Updated each year
  - Represents current, approved ACIP policy
  - Designed for implementation of ACIP policy
- Approved by
  - CDC Director
  - American College of Physicians
  - American Academy of Family Physicians
  - American College of Obstetricians and Gynecologists
  - American College of Nurse-Midwives
- Published in February, 2020
  - MMWR Notice to Readers – announcement of availability on ACIP website
  - Annals of Internal Medicine – published in entirety

# Updates in Adult Immunization Recommendations

# Updates in ACIP Recommendations for Adults

## Policy Statements Published after 2019 Adult Schedule Approval

- Human Papillomavirus (HPV) – June 2019 ACIP Meeting
  - Meites et al. MMWR Aug 2019; 68(32); 698-702
  - Catch-up vaccination for all persons through age 26
  - Shared clinical decision-making for persons 27-45 years
- Pneumococcal Vaccines – June 2019 ACIP Meeting
  - Matanock et al. MMWR Nov 2019; 68(46); 1069-1075
  - PPSV23 recommended for all persons 65 and older
  - Shared clinical decision-making for PCV13 in persons 65 and older
- Influenza Vaccines – June 2019 ACIP Meeting
  - Grohskopf et al. MMWR Aug 2019; 68(3); 1-21
  - Annual influenza vaccination recommended for all persons 6 months and older who do not have contraindications

# Updates in ACIP Recommendations for Adults

## Policy Statements Published after 2019 Adult Schedule Approval

- Hepatitis A Vaccines
  - All persons with HIV aged  $\geq 1$  year be routinely vaccinated
  - Vaccination recommended in settings for exposure
- Serogroup Meningococcal B Vaccines – June 2019 ACIP Meeting
  - For persons aged  $\geq 10$  years with complement deficiency, complement inhibitor use, asplenia, or who are microbiologists, MenB booster dose 1 year after primary series; booster every 2-3 years if risk remains
  - For persons aged  $\geq 10$  years determined by public health officials to be at increased risk during an outbreak, MenB booster dose if it has been  $\geq 1$  year since completion of primary series
- Tdap Vaccines – October 2019 ACIP Meeting
  - [Havers et al. MMWR Jan 2020; 69\(3\); 77-83](#)
  - Either Td vaccine or Tdap to be used for the decennial Td booster, tetanus prophylaxis for wound management, and for additional required doses in the catch-up immunization schedule if a person has received at least 1 Tdap dose

# HPV Updates

- Routine recommendations for HPV vaccination of adolescents have not changed
- Catch-up HPV vaccination is now recommended for all persons through age 26 years
- For adults aged 27 through 45 years, public health benefit of HPV vaccination in this age range is minimal; shared clinical decision-making is recommended because some persons who are not adequately vaccinated might benefit

# Pneumococcal Updates

- ACIP recommends a routine single dose of PPSV23 for adults aged  $\geq 65$  years
- Shared clinical decision-making is recommended regarding administration of PCV13 to persons aged  $\geq 65$  years who do not have an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant and who have not previously received PCV13
- If a decision to administer PCV13 is made, PCV13 should be administered first, followed by PPSV23 at least 1 year later.

# Pneumococcal Update

- ACIP asked CDC to examine the data on the PCV13 recommendation
- Pediatric use of PCV13 has indirectly reduced the incidence of PCV13-type disease among adults age 65 years and older
- Implementation of a PCV13 recommendation for all adults age 65 years and older in 2014 has had minimal impact on PCV13-type disease at the population level in this age group

# Influenza Updates

- Routine annual influenza vaccination is recommended for all persons aged  $\geq 6$  months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used
- Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are to be available for the 2019–20 season
- No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available

# Hepatitis A Updates

- ACIP recommends all persons with HIV aged  $\geq 1$  year be routinely vaccinated with Hepatitis A vaccine
- Hepatitis A vaccination is recommended for persons working in settings of exposure (e.g., those working in health care settings for injection or noninjection drug users or group homes and nonresidential day care facilities for developmentally disabled persons)
- Clotting factor disorders have been removed as an indication for Hepatitis A vaccine

# Meningococcal B Updates

- Persons  $\geq 10$  years with complement deficiency, complement inhibitor use, or asplenia or who are microbiologists should receive a MenB booster dose 1 year following completion of a MenB primary series
  - MenB booster doses every 2–3 years thereafter, for as long as the increased risk remains
- For persons  $\geq 10$  years determined by public health officials to be at increased risk during an outbreak, ACIP recommends a one-time booster dose if it has been 1 year or more since completion of a MenB primary series
- Adolescents and young adults 16-23 years (16-18 years preferred) not at increased risk for meningococcal disease may be vaccinated based on shared clinical decision-making

# Tdap Updates

- Either Td or Tdap to be used for:
  - The decennial Td booster
  - Tetanus prophylaxis for wound management
  - For additional required doses in the catch-up immunization schedule if a person has received at least 1 Tdap dose

# Shared Clinical Decision-Making Recommendation

- Shared clinical decision-making (SCDM) vaccinations are not recommended for everyone in a particular age group or everyone in an identifiable risk group
- SCDM recommendations are individually based and informed by a decision process between the health care provider and the patient or parent/guardian
- The key distinction between routine, catch-up, and risk-based recommendations and SCDM recommendations is the default decision to vaccinate
- ACIP makes SCDM recommendations when individuals may benefit from vaccination, but broad vaccination of people in that group is unlikely to have population-level impacts

# Harmonization with Child and Adolescent Schedule

# Harmonization with Child and Adolescent Schedule

- Overlapping vaccinations
  - Hib, hepatitis A, hepatitis B, HPV, influenza, MMR, meningococcal, pneumococcal, Tdap/Td, varicella
- Harmonize language, text structure, graphics (to extent possible)
- Collaborators
  - Adult Immunization WG, Child/Adolescent Immunization WG, disease and vaccination SMEs, communication and training staff

# Harmonization with Child and Adolescent Schedule

- Included trade names on list (trade names used in HepA, HepB, MenACWY, MenB notes)
- Organized notes by heading (“routine vaccination,” “shared clinical decision-making,” and “special situations”)
- Revised notes for brevity, clarity, consistency
- Used bold text to highlight population or indication for which vaccination recommended, minimized use of specialized text
- Removed articles, conjunctions, other words if meaning not compromised
- Used consistent text structure and language (e.g., 3-dose series HPV vaccine at 0, 1-2, 6 months)

*Recommended Adult Immunization Schedule,  
United States, 2020*

**Cover Page**

**Recommended Adult Immunization Schedule**

# Recommended Adult Immunization Schedule for ages 19 years or older

UNITED STATES

# 2020

## How to use the adult immunization schedule

- 1 Determine recommended vaccinations by age (**Table 1**)
- 2 Assess need for additional recommended vaccinations by medical condition and other indications (**Table 2**)
- 3 Review vaccine types, frequencies, and intervals and considerations for special situations (**Notes**)

Recommended by the Advisory Committee on Immunization Practices ([www.cdc.gov/vaccines/acip](http://www.cdc.gov/vaccines/acip)) and approved by the Centers for Disease Control and Prevention ([www.cdc.gov](http://www.cdc.gov)).  
American College of Nurse-Midwives ([www.midwife.org](http://www.midwife.org)).

## Instructions on how to use

### Vaccines in the Adult Immunization Schedule\*

Vaccines	Abbreviations	Trade names
<i>Haemophilus influenzae</i> type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB® HepSiv-B®
Human papillomavirus vaccine	HPV vaccine	Gardasil 9®
Influenza vaccine (inactivated)	IIV	Many brands
Influenza vaccine (live, attenuated)	LAIV	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RIV	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R® II
Meningococcal serogroups A, C, W, Y vaccine	MenACWY	Menactra® Menveo®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Pneumococcal 13-valent conjugate vaccine	PCV13	Pneumovax 13®
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax® 23
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix
Zoster vaccine live	ZVL	Zostavax®

\*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

### Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967

### Injury claims

All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV, ZVL) vaccines are covered by the Vaccine Injury Compensation Program. Information on how to file a vaccine injury claim is available at [www.hrsa.gov/vaccinecompensation](http://www.hrsa.gov/vaccinecompensation).

### Questions or comments

Contact [www.cdc.gov/cdc-info](http://www.cdc.gov/cdc-info) or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules App for providers at [www.cdc.gov/vaccines/schedules/hcp/schedule-app.html](http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html).

### Helpful information

- Complete ACIP recommendations: [www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html)
- General Best Practice Guidelines for Immunization (including contraindications and precautions): [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html)
- Vaccine information statements: [www.cdc.gov/vaccines/hcp/vis/index.html](http://www.cdc.gov/vaccines/hcp/vis/index.html)
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): [www.cdc.gov/vaccines/pubs/surv-manual](http://www.cdc.gov/vaccines/pubs/surv-manual)
- Travel vaccine recommendations: [www.cdc.gov/travel](http://www.cdc.gov/travel)
- Recommended Child and Adolescent Immunization Schedule, United States, 2020: [www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html](http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html)



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

# Recommended Adult Immunization Schedule for ages 19 years or older

UNITED STATES

# 2020

## How to use the adult immunization schedule

- 1 Determine recommended vaccinations by age (**Table 1**)
- 2 Assess need for additional recommended vaccinations by medical condition and other indications (**Table 2**)
- 3 Review vaccine types, frequencies, and intervals and considerations for special situations (**Notes**)

Recommended by the Advisory Committee on Immunization Practices ([www.cdc.gov/vaccines/acip](http://www.cdc.gov/vaccines/acip)) and approved by the Centers for Disease Control and Prevention ([www.cdc.gov](http://www.cdc.gov)), American College of Physicians ([www.acponline.org](http://www.acponline.org)), American Academy of Family Physicians ([www.aafp.org](http://www.aafp.org)), American College of Obstetricians and Gynecologists ([www.acog.org](http://www.acog.org)), and American College of Nurse-Midwives ([www.midwife.org](http://www.midwife.org)).

### Vaccines in the Adult Immunization Schedule\*

Vaccines	Abbreviations	Trade names
<i>Haemophilus influenzae</i> type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB® Hepilisav-B®
Human papillomavirus vaccine	HPV vaccine	Gardasil 9®
Influenza vaccine (inactivated)	IIV	Many brands
Influenza vaccine (live, attenuated)	LAIV	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RV	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R® II
Meningococcal serogroups A, C, W, Y vaccine	MenACWY	Menactra® Menveo®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Pneumococcal 13-valent conjugate vaccine	PCV13	Pneumovax 13®
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax® 23
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix
Zoster vaccine live	ZVL	Zostavax®

\*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

### Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967

### Injury claims

All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV, ZVL) vaccines are covered by the Vaccine Injury Compensation Program. Information on how to file a vaccine injury claim is available at [www.hrsa.gov/vaccinecompensation](http://www.hrsa.gov/vaccinecompensation).

### Questions or comments

Contact [www.cdc.gov/cdc-info](http://www.cdc.gov/cdc-info) or 800-CDC-INFO (800-232-4636), in English or Spanish.

**List of vaccines, abbreviations, trade names**

### Helpful information

- Complete ACIP recommendations: [www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html)
- General Best Practice Guidelines for Immunization (including contraindications and precautions): [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html)
- Vaccine information statements: [www.cdc.gov/vaccines/hcp/vis/index.html](http://www.cdc.gov/vaccines/hcp/vis/index.html)
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): [www.cdc.gov/vaccines/pubs/surv-manual](http://www.cdc.gov/vaccines/pubs/surv-manual)
- Travel vaccine recommendations: [www.cdc.gov/travel](http://www.cdc.gov/travel)
- Recommended Child and Adolescent Immunization Schedule, United States, 2020: [www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html](http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html)



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

# Recommended Adult Immunization Schedule for ages 19 years or older

UNITED STATES  
**2020**

## How to use the adult immunization schedule

- 1 Determine recommended vaccinations by age (**Table 1**)
- 2 Assess need for additional recommended vaccinations by medical condition and other indications (**Table 2**)
- 3 Review vaccine types, frequencies, and intervals and considerations for special situations (**Notes**)

Recommended by the Advisory Committee on Immunization Practices ([www.cdc.gov/vaccines/acip](http://www.cdc.gov/vaccines/acip)) and approved by the Centers for Disease Control and Prevention ([www.cdc.gov](http://www.cdc.gov)), American College of Physicians ([www.acponline.org](http://www.acponline.org)), American Academy of Family Physicians ([www.aafp.org](http://www.aafp.org)), American College of Obstetricians and Gynecologists ([www.acog.org](http://www.acog.org)), and American College of Nurse-Midwives ([www.midwife.org](http://www.midwife.org)).

### Vaccines in the Adult Immunization Schedule\*

Vaccines	Abbreviations	Trade names
<i>Haemophilus influenzae</i> type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine		
Hepatitis A and hepatitis B vaccine		
Hepatitis B vaccine		Recombivax HB® Hepilisav-B®
Human papillomavirus vaccine	HPV vaccine	Gardasil 9®
Influenza vaccine (inactivated)	IIV	Many brands
Influenza vaccine (live, attenuated)	LAIV	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RV	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine		
Meningococcal serogroups A, C, W, Y vaccine		
Meningococcal serogroup B vaccine		
Pneumococcal 13-valent conjugate vaccine		
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax® 23
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix
Zoster vaccine live	ZVL	Zostavax®

Compartmentalized  
information

Added resource on disease  
case identification and  
outbreak response

### Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or 800-822-7967

### Injury claims

All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV, ZVL) vaccines are covered by the Vaccine Injury Compensation Program. Information on how to file a vaccine injury claim is available at [www.hrsa.gov/vaccinecompensation](http://www.hrsa.gov/vaccinecompensation).

### Questions or comments

Contact [www.cdc.gov/cdc-info](http://www.cdc.gov/cdc-info) or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.



Download the CDC Vaccine Schedules App for providers at [www.cdc.gov/vaccines/schedules/hcp/schedule-app.html](http://www.cdc.gov/vaccines/schedules/hcp/schedule-app.html).

### Helpful Information

- Complete ACIP recommendations: [www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html)
- General Best Practice Guidelines for Immunization (including contraindications and precautions): [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html)
- Vaccine information statements: [www.cdc.gov/vaccines/hcp/vis/index.html](http://www.cdc.gov/vaccines/hcp/vis/index.html)
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): [www.cdc.gov/vaccines/pubs/surv-manual](http://www.cdc.gov/vaccines/pubs/surv-manual)
- Travel vaccine recommendations: [www.cdc.gov/travel](http://www.cdc.gov/travel)
- Recommended Child and Adolescent Immunization Schedule, United States, 2020: [www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html](http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html)

\*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

# Table 1

## Recommended Adult Immunization Schedule by Age Group

**Table 1** Recommended Adult Immunization Schedule by Age Group, United States, 2020

Vaccine	19–26 years	27–49 years	50–64 years	≥65 years
Influenza inactivated (IIV) or Influenza recombinant (RIV)		1 dose annually		
Influenza live, attenuated (LAIV)		1 dose annually		
Tetanus, diphtheria, and acellular pertussis (Tdap or Td)		1 dose of Tdap, then Td or Tdap booster every 10 years		
Measles, mumps, rubella (MMR)		2 doses depending on indication (if born in 1957 or later)		
Varicella (VAR)	2 doses (if born in 1980 or later)		2 doses	
Zoster recombinant (RZV) (preferred)			2 doses	
Zoster live (ZVL)			1 dose	
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years		
Pneumococcal conjugate (PCV13)	1 dose			65 years and older
Pneumococcal polysaccharide (PPSV23)	1 or 2 doses depending on indication			1 dose
Hepatitis A (HepA)	2 or 3 doses depending on vaccine			
Hepatitis B (HepB)	2 or 3 doses depending on vaccine			
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations			
Meningococcal B (MenB)	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations			
<i>Haemophilus influenzae</i> type b (Hib)	19 through 23 years	1 or 3 doses depending on indication		

Age groups 19–21 years and 22–26 years have been combined

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
 
 Recommended vaccination for adults with an additional risk factor or another indication
 

 Recommended vaccination based on shared clinical decision-making
 

 No recommendation/Not applicable

**Table 1** Recommended Adult Immunization Schedule by Age Group, United States, 2020

Vaccine	19–26 years	27–49 years	50–64 years	≥65 years
Influenza inactivated (IIV) or Influenza recombinant (RIV) <b>or</b> Influenza live, attenuated (LAIV)	1 dose annually			
Tetanus, diphtheria, pertussis (Tdap or Td)	1 dose Tdap, then Td or Tdap booster every 10 years			
Measles, mumps, rubella (MMR)	1 or 2 doses depending on indication (if born in 1957 or later)			
Varicella (VAR)	2 doses (if born in 1980 or later)		2 doses	
Zoster recombinant (RZV) (preferred) <b>or</b> Zoster live (ZVL)			2 doses	1 dose
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years		
Pneumococcal conjugate (PCV13)	1 dose			65 years and older
Pneumococcal polysaccharide (PPSV23)				1 dose
Hepatitis A (HepA)				
Hepatitis B (HepB)	2 or 3 doses depending on vaccine			
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations			
Meningococcal B (MenB)	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations			
<i>Haemophilus influenzae</i> type b (Hib)	19 through 23 years	1 or 3 doses depending on indication		

**HPV row combined for males and females**

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
  Recommended vaccination for adults with an additional risk factor or another indication
  Recommended vaccination based on shared clinical decision-making
  No recommendation/Not applicable

**Table 1** Recommended Adult Immunization Schedule by Age Group, United States, 2020

Vaccine	19–26 years	27–49 years	50–64 years	≥65 years
Influenza inactivated (IIV) or Influenza recombinant (RIV) <b>or</b> Influenza live, attenuated (LAIV)	1 dose annually			
Tetanus, diphtheria, pertussis (Tdap or Td)	1 dose Tdap, then Td or Tdap booster every 10 years			
Measles, mumps, rubella (MMR)	1 or 2 doses depending on indication (if born in 1957 or later)			
Varicella (VAR)	2 doses (if born in 1980 or later)			
Zoster recombinant (RZV) (preferred) <b>or</b> Zoster live (ZVL)				1 dose
Human papillomavirus (HPV)	2 or 3 doses depending on age at initial vaccination or condition	27 through 45 years		
Pneumococcal conjugate (PCV13)		1 dose		65 years and older
Pneumococcal polysaccharide (PPSV23)		1 or 2 doses depending on indication		1 dose
Hepatitis A (HepA)	2 or 3 doses depending on vaccine			
Hepatitis B (HepB)	2 or 3 doses depending on vaccine			
Meningococcal A, C, W, Y (MenACWY)	1 or 2 doses depending on indication, see notes for booster recommendations			
Meningococcal B (MenB)	19 through 23 years	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations		
Haemophilus influenzae type b (Hib)	1 or 3 doses depending on indication			

Blue shading indicates shared clinical decision-making

  Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
   Recommended vaccination for adults with an additional risk factor or another indication
  Recommended vaccination based on shared clinical decision-making
  No recommendation/Not applicable

## **Table 2**

# **Recommended Adult Immunization Schedule by Medical Condition and Other Indications**

**Table 2** Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2020

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 count		Asplenia, complement deficiencies	End-stage renal disease; or on hemodialysis	Heart or lung disease, alcoholism <sup>1</sup>	Chronic liver disease	Diabetes	Health care personnel <sup>2</sup>	Men who have sex with men
			<200	≥200							
IIV or RIV or LAIV											1 dose annually
											1 dose annually
Tdap or Td	1 dose Tdap during pregnancy										1 dose Tdap
MMR											
VAR											2 doses
RZV (preferred) or ZVL	DELAY										2 doses at age ≥50 years or 1 dose at age ≥60 years
HPV	DELAY										3 doses through age 26 years or 2 or 3 doses through age 26 years
PCV13											1 dose
PPSV23											1, 2, or 3 doses depending on age and indication
HepA											2 or 3 doses depending on vaccine
HepB											2 or 3 doses depending on vaccine
MenACWY											1 or 2 doses depending on indication, see notes for booster recommendations
MenB	PRECAUTION										2 or 3 doses depending on vaccine and indication, see notes for booster recommendations
Hib											3 doses HSCT <sup>3</sup> recipients only or 1 dose

NOT RECOMMENDED

Red text states not recommended instead of contraindicated

  Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
   Recommended vaccination for adults with an additional risk factor or another indication
   Precaution—vaccination might be indicated if benefit of protection outweighs risk of adverse reaction
   Delay vaccination until after pregnancy if vaccine is indicated
   Not recommended/contraindicated—vaccine should not be administered
   No recommendation/Not applicable

1. Precaution for LAIV does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.

**Table 2** Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2020

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 count		Asplenia, complement deficiencies	End-stage renal disease; or on hemodialysis	Heart or lung disease, alcoholism <sup>1</sup>	Chronic liver disease	Diabetes	Health care personnel <sup>2</sup>	Men who have sex with men
			<200	≥200							
IIV or RIV or LAIV	1 dose annually										
	NOT RECOMMENDED					PRECAUTION				1 dose annually	
Tdap or Td	1 dose Tdap each pregnancy	1 dose Tdap, then Td or Tdap booster every 10 years									
MMR	NOT RECOMMENDED			1 or 2 doses depending on indication							
VAR	NOT RECOMMENDED			2 doses							
RZV (preferred) or ZVL	DELAY				2 doses at age ≥50 years						
	NOT RECOMMENDED			1 dose at age ≥60 years							
HPV	DELAY	3 doses through age 26 years			2 or 3 doses through age 26 years						
PCV13		1 dose									
PPSV23		1 dose depending on age and indication									
HepA		1 dose depending on vaccine									
HepB		2 or 3 doses depending on vaccine									
MenACWY	1 or 2 doses depending on indication, see notes for booster recommendations										
MenB	PRECAUTION	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations									
Hib		3 doses HSCT <sup>3</sup> recipients only	1 dose								

**HPV row combined for males and females**

  Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
   Recommended vaccination for adults with an additional risk factor or another indication
   Precaution—vaccination might be indicated if benefit of protection outweighs risk of adverse reaction
   Delay vaccination until after pregnancy if vaccine is indicated
   Not recommended/contraindicated—vaccine should not be administered
   No recommendation/Not applicable

1. Precaution for LAIV does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.

**Table 2** Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2020

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 count		Asplenia, complement deficiencies	End-stage renal disease; or on hemodialysis	Heart or lung disease, alcoholism <sup>1</sup>	Chronic liver disease	Diabetes	Health care personnel <sup>2</sup>	Men who have sex with men	
			<200	≥200								
IIV or RIV or LAIV	1 dose annually											
	NOT RECOMMENDED					PRECAUTION				1 dose annually		
Tdap or Td	1 dose Tdap each pregnancy	1 dose Tdap, then Td or Tdap booster every 10 years										
MMR	NOT RECOMMENDED			1 or 2 doses depending on indication								
VAR	NOT RECOMMENDED			2 doses								
RZV (preferred) or ZVL	DELAY				2 doses at age ≥50 years							
	NOT RECOMMENDED			1 dose at age ≥60 years								
HPV	DELAY	3 doses through age 26 years			2 or 3 doses through age 26 years							
PCV13		1 dose										
PPSV23		1 dose										
HepA		1 dose										
HepB		1 dose										
MenACWY	1 or 2 doses depending on indication, see notes for booster recommendations											
MenB	PRECAUTION	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations										
Hib		3 doses HSCT <sup>3</sup> recipients only	1 dose									

**HepA vaccine recommended for all persons ≥1 year living with HIV**

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
  Recommended vaccination for adults with an additional risk factor or another indication
  Precaution—vaccination might be indicated if benefit of protection outweighs risk of adverse reaction
  Delay vaccination until after pregnancy if vaccine is indicated
  Not recommended/contraindicated—vaccine should not be administered
  No recommendation/Not applicable

1. Precaution for LAIV does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.

# Notes

## Recommended Adult Immunization Schedule

**Haemophilus influenzae type b vaccination****Special situations**

- **Anatomical or functional asplenia (including sickle cell disease):** 1 dose if previously did not receive Hib; if elective splenectomy, 1 dose, preferably at least 14 days before splenectomy
- **Hematopoietic stem cell transplant (HSCT):** 3-dose series 4 weeks apart starting 6–12 months after successful transplant, regardless of Hib vaccination history

**Hepatitis A vaccination****Routine vaccination**

- **Not at risk but want protection from hepatitis A** (identification of risk factor not required): 2-dose series HepA (Havrix 6–12 months apart or Vaqta 6–18 months apart [minimum interval: 6 months]) or 3-dose series HepA-HepB (Twinrix at 0, 1, 6 months [minimum intervals: 4 weeks between doses 1 and 2/5 months between doses 2 and 3])

**Special situations**

- **At risk for hepatitis A virus infection:** 2-dose series HepA or 3-dose series HepA-HepB as above
  - **Chronic liver disease** (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
  - **HIV Infection**
  - **Men who have sex with men**
  - **Injection or noninjection drug use**
  - **Persons experiencing homelessness**
  - **Work with hepatitis A virus** in research laboratory or with nonhuman primates with hepatitis A virus infection
  - **Travel in countries with high or intermediate endemic hepatitis A**
  - **Close, personal contact with international adoptee** (e.g., household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival)

- **Pregnancy** if at risk for infection or from infection during pregnancy
- **Settings for exposure, including** targeting services to injection or nonusers or group homes and nonresidential facilities for developmentally disabled persons (individual risk factor screening not required)

**Hepatitis B vaccination****Routine vaccination**

- **Not at risk but want protection from hepatitis B** (identification of risk factor not required): 2- or 3-dose series (2-dose series Heplisav-B at least 4 weeks apart [2-dose series HepB only applies when 2 doses of Heplisav-B are used at least 4 weeks apart] or 3-dose series Engerix-B or Recombivax HB at 0, 1, 6 months [minimum intervals: 4 weeks between doses 1 and 2/8 weeks between doses 2 and 3/16 weeks between doses 1 and 3]) or 3-dose series HepA-HepB (Twinrix at 0, 1, 6 months [minimum intervals: 4 weeks between doses 1 and 2/5 months between doses 2 and 3])

**Special situations**

- **At risk for hepatitis B virus infection:** 2-dose (Heplisav-B) or 3-dose (Engerix-B, Recombivax HB) series or 3-dose series HepA-HepB (Twinrix) as above
  - **Chronic liver disease** (e.g., persons with hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] level greater than twice the upper limit of normal)
  - **Current or recent injection drug use**
  - **Percutaneous or mucosal risk for exposure to blood** (e.g., household contacts of HBsAg-positive persons; residents and staff of facilities for developmentally disabled persons; health care and public safety personnel with reasonably anticipated risk for

**Recommended in settings for exposure**

- **Incarcerated persons**
- **Travel in countries with high or intermediate endemic hepatitis B**
- **Pregnancy** if at risk for infection or severe outcome from infection during pregnancy (Heplisav-B not currently recommended due to lack of safety data in pregnant women)

**Human papillomavirus vaccination****Routine vaccination**

- **HPV vaccination recommended for all adults through age 26 years:** 2- or 3-dose series depending on age at initial vaccination or condition:
  - **Age 15 years or older at initial vaccination:** 3-dose series at 0, 1–2, 6 months (minimum intervals: 4 weeks between doses 1 and 2/12 weeks between doses 2 and 3/5 months between doses 1 and 3; repeat dose if administered too soon)
  - **Age 9 through 14 years at initial vaccination and received 1 dose or 2 doses less than 5 months apart:** 1 dose
  - **Age 9 through 14 years at initial vaccination and received 2 doses at least 5 months apart:** HPV vaccination complete, no additional dose needed.
- **If completed valid vaccination series with any HPV vaccine, no additional doses needed**

**Shared clinical decision-making**

- **Age 27 through 45 years based on shared clinical decision-making:**
  - 2- or 3-dose series as above

**Special situations**

- **Pregnancy through age 26 years:** HPV vaccination is not recommended until after pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination

**Recommended for all persons ≥1 year living with HIV**

ated body fluids; dialysis, and diabetes mellitus age of treating

# Notes Recommended Adult Immunization Schedule, United States, 2020

## Haemophilus influenzae type b vaccination

### Special situations

- **Anatomical or functional asplenia (including sickle cell disease):** 1 dose if previously did not receive Hib; if elective splenectomy, 1 dose, preferably at least 14 days before splenectomy
- **Hematopoietic stem cell transplant (HSCT):** 3-dose series 4 weeks apart starting 6–12 months after successful transplant, regardless of Hib vaccination history

## Hepatitis A vaccination

### Routine vaccination

- **Not at risk but want protection from hepatitis A** (identification of risk factor not required): 2-dose series HepA (Havrix 6–12 months apart or Vaqta 6–18 months apart [minimum interval: 6 months]) or 3-dose series HepA-HepB (Twinrix at 0, 1, 6 months [minimum intervals: 4 weeks between doses 1 and 2/5 months between doses 2 and 3])

### Special situations

- **At risk for hepatitis A virus infection:** 2-dose series HepA or 3-dose series HepA-HepB as above
  - **Chronic liver disease** (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
  - **HIV Infection**
  - **Men who have sex with men**
  - **Injection or noninjection drug use**
  - **Persons experiencing homelessness**
  - **Work with hepatitis A virus** in research laboratory or with nonhuman primates with hepatitis A virus infection
  - **Travel in countries with high or intermediate endemic hepatitis A**
  - **Close, personal contact with international adoptee** (e.g., household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival)

- **Pregnancy** if at risk for infection or severe outcome from infection during pregnancy
- **Settings for exposure, including** health care settings targeting services to injection or noninjection drug users or group homes and nonresidential day care facilities for developmentally disabled persons (individual risk factor screening not required)

## Hepatitis B vaccination

### Routine vaccination

- **Not at risk but want protection from hepatitis B** (identification of risk factor not required): 2- or 3-dose series (2-dose series Heplisav-B at least 4 weeks apart [2-dose series HepB only applies when 2 doses of Heplisav-B are used at least 4 weeks apart] or 3-dose

Catch up recommended for all persons through age 26 years

and 2/5 months between doses 2 and 3])

### Special situations

- **At risk for hepatitis B virus infection:** 2-dose (Heplisav-B) or 3-dose (Engerix-B, Recombivax HB) series or 3-dose series HepA-HepB (Twinrix) as above
  - **Chronic liver disease** (e.g., persons with hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice upper limit of normal)
  - **Current or recent injection drug use**
  - **Percutaneous or mucosal risk for exposure to blood** (e.g., household contacts of HBsAg-positive persons; residents and staff of facilities for developmentally disabled persons; health care and public safety personnel with reasonably anticipated risk for

Shared clinical decision-making recommended for persons 27-45 years

exposure to blood or blood-contaminated body fluids; hemodialysis, peritoneal dialysis, home dialysis, and predialysis patients; persons with diabetes mellitus age younger than 60 years and, at discretion of treating clinician, those age 60 years or older)

- **Incarcerated persons**
- **Travel in countries with high or intermediate endemic hepatitis B**

- **Pregnancy** if at risk for infection or severe outcome from infection during pregnancy (Heplisav-B not currently recommended due to lack of safety data in pregnant women)

## Human papillomavirus vaccination

### Routine vaccination

- **HPV vaccination recommended for all adults through age 26 years:** 2- or 3-dose series depending on age at initial vaccination or condition:
  - **Age 15 years or older at initial vaccination:** 3-dose series at 0, 1–2, 6 months (minimum intervals: 4 weeks between doses 1 and 2/12 weeks between doses 2 and 3/5 months between doses 1 and 3; repeat dose if administered too soon)
  - **Age 9 through 14 years at initial vaccination and received 1 dose or 2 doses less than 5 months apart:** 1 dose
  - **Age 9 through 14 years at initial vaccination and received 2 doses at least 5 months apart:** HPV vaccination complete, no additional dose needed.
- **If completed valid vaccination series with any HPV**

### Shared clinical decision-making

Age 27 through 45 years: shared clinical decision-making:

- 2- or 3-dose series as above

### Special situations

- **Pregnancy through age 26 years:** HPV vaccination is not recommended until after pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination

## Influenza vaccination

## Routine vaccination

- **Persons age 6 months or older:** 1 dose any influenza vaccine appropriate for age and health status annually
- For additional guidance, see [www.cdc.gov/flu/professionals/index.htm](http://www.cdc.gov/flu/professionals/index.htm)

## Special situations

- **Egg allergy, hives only:** 1 dose any influenza vaccine appropriate for age and health status annually
- **Egg allergy more severe than hives** (e.g., angioedema, respiratory distress): 1 dose any influenza vaccine appropriate for age and health status annually in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions
- **LAIV should not be used** in persons with the following conditions or situations:
  - History of severe allergic reaction to any vaccine component (excluding egg) or to a previous dose of any influenza vaccine
  - Immunocompromised due to any cause (including medications and HIV infection)
  - Anatomic or functional asplenia
  - Cochlear implant
  - Cerebrospinal fluid–oropharyngeal communication
  - Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
  - Pregnancy
  - Received influenza antiviral medications within the previous 48 hours
- **History of Guillain-Barré syndrome within 6 weeks of previous dose of influenza vaccine:** Generally should not be vaccinated unless vaccination benefits outweigh risks for those at higher risk for severe complications from influenza

## Measles, mumps, and rubella vaccination

## Routine vaccination

- **No evidence of immunity to measles, mumps, or rubella:** 1 dose
- **Evidence of immunity:** Born before 1957 (health care personnel, see below), documentation of receipt of MMR vaccine, laboratory evidence of immunity or disease (diagnosis of disease without laboratory confirmation is not evidence of immunity)

## Special situations

- **Pregnancy with no evidence of immunity to rubella:** MMR contraindicated during pregnancy; after pregnancy (before discharge from health care facility), 1 dose
- **Nonpregnant women of childbearing age with no evidence of immunity to rubella:** 1 dose
- **HIV infection with CD4 count  $\geq 200$  cells/ $\mu$ L for at least 6 months and no evidence of immunity to**

## Bulleted list of situations where LAIV should not be used

- personal contacts of immunocompromised persons with no evidence of immunity to measles, mumps, or rubella:** 2-dose series at least 4 weeks apart if previously did not receive any doses of MMR or 1 dose if previously received 1 dose MMR
- **Health care personnel:**
  - **Born in 1957 or later with no evidence of immunity to measles, mumps, or rubella:** 2-dose series at least 4 weeks apart for measles or mumps or at least 1 dose for rubella
  - **Born before 1957 with no evidence of immunity to measles, mumps, or rubella:** Consider 2-dose series at least 4 weeks apart for measles or mumps or 1 dose for rubella

## Meningococcal vaccination

## Special situations for MenACWY

- **Anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:** 2-dose series MenACWY (Menactra, Menveo) at least 8 weeks apart and revaccinate every 5 years if risk remains
- **Travel in countries with hyperendemic or epidemic meningococcal disease, microbiologists routinely exposed to *Neisseria meningitidis*:** 1 dose MenACWY (Menactra, Menveo) and revaccinate every 5 years if risk remains
- **First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) and military recruits:** 1 dose MenACWY (Menactra, Menveo)

## Shared clinical decision-making for MenB

- **Adolescents and young adults age 16 through 23 years (age 16 through 18 years preferred) not at increased risk for meningococcal disease:** Based on shared clinical decision-making, 2-dose series MenB-4C at least 1 month apart or 2-dose series MenB-FHbp at 0, 6 months (if dose 2 was administered less than 6 months after dose 1, administer dose 3 at least 4 months after dose 2); MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series)

## Special situations for MenB

- **Anatomical or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use, microbiologists routinely exposed to *Neisseria meningitidis*:** 2-dose primary series MenB-4C (Bexsero) at least 1 month apart or 3-dose primary series MenB-FHbp (Trumenba) at 0, 1–2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed); MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series); 1 dose MenB booster 1 year after primary series and revaccinate every 2–3 years if risk remains
- **Pregnancy:** Delay MenB until after pregnancy unless at increased risk and vaccination benefits outweigh potential risks

## Notes

### Recommended Adult Immunization Schedule, United States, 2020

#### Influenza vaccination

##### Routine vaccination

- **Persons age 6 months or older:** 1 dose any influenza vaccine appropriate for age and health status annually
- For additional guidance, see [www.cdc.gov/flu/professionals/index.htm](http://www.cdc.gov/flu/professionals/index.htm)

##### Special situations

- **Egg allergy, hives only:** 1 dose any influenza vaccine appropriate for age and health status annually
- **Egg allergy more severe than hives** (e.g., angioedema, respiratory distress): 1 dose any influenza vaccine appropriate for age and health status annually in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions
- **LAIV should not be used** in persons with the following conditions or situations:
  - History of severe allergic reaction to any vaccine component (excluding egg) or to a previous dose of any influenza vaccine
  - Immunocompromised due to any cause (including medications and HIV infection)
  - Anatomic or functional asplenia
  - Cochlear implant
  - Cerebrospinal fluid–oropharyngeal communication
  - Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
  - Pregnancy
  - Received influenza antiviral medications within the previous 48 hours
- **History of Guillain-Barré syndrome within 6 weeks of previous dose of influenza vaccine:** Generally should not be vaccinated unless vaccination benefits outweigh risks for those at higher risk for severe complications from influenza

#### Measles, mumps, and rubella vaccination

##### Routine vaccination

- **No evidence of immunity to measles, mumps, or rubella:** 1 dose
  - **Evidence of immunity:** Born before 1957 (health care personnel, see below), documentation of receipt of MMR vaccine, laboratory evidence of immunity or disease (diagnosis of disease without laboratory confirmation is not evidence of immunity)

##### Special situations

- **Pregnancy with no evidence of immunity to rubella:** MMR contraindicated during pregnancy; after pregnancy (before discharge from health care facility), 1 dose
- **Nonpregnant women of childbearing age with no evidence of immunity to rubella:** 1 dose
- **HIV infection with CD4 count  $\geq 200$  cells/ $\mu$ L for at least 6 months and no evidence of immunity to measles, mumps, or rubella:** 2-dose series at least 4 weeks apart; MMR contraindicated in HIV infection with CD4 count  $< 200$  cells/ $\mu$ L

Shared clinical decision-making for adolescents and young adults aged 16–23 years who are not at increased risk

Recommendation for booster doses every 2–3 years if risk remains

#### Meningococcal vaccination

##### Special situations for MenACWY

- **Anatomical or functional asplenia** (including sickle cell disease), **HIV infection**, **persistent complement component deficiency**, **complement inhibitor** (e.g., eculizumab, ravulizumab) **use:** 2-dose series MenACWY (Menactra, Menveo) at least 8 weeks apart and revaccinate every 5 years if risk remains
- **Travel in countries with hyperendemic or epidemic meningococcal disease**, **microbiologists routinely exposed to *Neisseria meningitidis*:** 1 dose MenACWY (Menactra, Menveo) and revaccinate every 5 years if risk remains
- **First-year college students who live in residential housing** (if not previously vaccinated at age 16 years or older) **and military recruits:** 1 dose MenACWY

##### Shared clinical decision-making for MenB

Adolescents and young adults aged 16–23 years (age 16 through 18 years preferred) **not at increased risk for meningococcal disease:** Based on shared clinical decision-making, 2-dose series MenB-4C at least 1 month apart or 2-dose series MenB-FHbp at 0, 6 months (if dose 2 was administered less than 6 months after dose 1, administer dose 3 at least 4 months after dose 2); MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series)

##### Special situations for MenB

- **Anatomical or functional asplenia** (including sickle cell disease), **persistent complement component deficiency**, **complement inhibitor** (e.g., eculizumab, ravulizumab) **use, microbiologists routinely exposed to *Neisseria meningitidis*:** 2-dose primary series MenB-4C (Bexsero) at least 1 month apart or 3-dose primary series MenB-FHbp (Trumenba) at 0, 1–2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed); MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series); 1 dose MenB booster 1 year after primary series and revaccinate every 2–3 years if risk remains
- **Pregnancy:** Delay MenB until after pregnancy unless at increased risk and vaccination benefits outweigh potential risks

## Pneumococcal vaccination

## Routine vaccination

- **Age 65 years or older** (immunocompetent—see [www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s\\_cid=mm6846a5\\_w](http://www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s_cid=mm6846a5_w)): 1 dose PPSV23
- If PPSV23 was administered prior to age 65 years, administer 1 dose PPSV23 at least 5 years after previous dose

## Shared clinical decision-making

- **Age 65 years and older** (immunocompetent): 1 dose PCV13 based on **shared clinical decision-making**
- If both PCV13 and PPSV23 are to be administered, PCV13 should be administered first
- PCV13 and PPSV23 should be administered at least 1 year apart
- PCV13 and PPSV23 should not be administered during the same visit

## Special situations

(see [www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s\\_cid=mm6846a5\\_w](http://www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s_cid=mm6846a5_w))

- **Age 19 through 64 years with chronic medical conditions (chronic heart [excluding hypertension], lung, or liver disease, diabetes), alcoholism, or cigarette smoking:** 1 dose PPSV23
- **Age 19 years or older with immunocompromising conditions (congenital or acquired immunodeficiency [including B- and T-lymphocyte deficiency, complement deficiencies, phagocytic disorders, HIV infection], chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, iatrogenic immunosuppression [e.g., drug or radiation therapy], solid organ transplant, multiple myeloma) or anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies):** 1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later, then another dose PPSV23 at least 5 years after previous PPSV23; at age 65 years or older, administer 1 dose PPSV23 at least 5 years after most recent PPSV23 (note: only 1 dose PPSV23 recommended at age 65 years or older)

- **Age 19 years or older with cerebrospinal fluid leak or cochlear implant:** 1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later; at age 65 years or older, administer another dose PPSV23 at least 5 years after PPSV23 (note: only 1 dose PPSV23 recommended at age 65 years or older)

## Tetanus, diphtheria, and pertussis vaccination

## Routine vaccination

- **Previously did not receive Tdap at or after age 11**

## Shared clinical decision-making recommendation for PCV-13

but preferred as first dose); Td or Tdap every 10 years thereafter

- **Pregnancy:** 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36
- For information on use of Td or Tdap as tetanus prophylaxis in wound management, see [www.cdc.gov/mmwr/volumes/67/rr/mm6702a1.htm](http://www.cdc.gov/mmwr/volumes/67/rr/mm6702a1.htm)

## Varicella vaccination

## Routine vaccination

- **No evidence of immunity to varicella:** 2-dose series 4–8 weeks apart if previously did not receive varicella-containing vaccine (VAR or MMRV [measles-mumps-rubella-varicella vaccine] for children); if previously received 1 dose varicella-containing vaccine, 1 dose at least 4 weeks after first dose
- Evidence of immunity: U.S.-born before 1980 (except for pregnant women and health care personnel [see below]), documentation of 2 doses varicella-containing vaccine at least 4 weeks apart, diagnosis or verification of history of varicella or herpes zoster by a health care provider, laboratory evidence of immunity or disease

## Special situations

- **Pregnancy with no evidence of immunity to varicella:** VAR contraindicated during pregnancy; after pregnancy (before discharge from health care facility) 1 dose if previously received 1 dose varicella-containing vaccine or dose 1 of 2-dose series (dose 2: 4–8 weeks later) if previously did not receive any varicella-containing vaccine, regardless of whether U.S.-born before 1980
- **Health care personnel with no evidence of immunity to varicella:** 1 dose if previously received 1 dose varicella-containing vaccine; 2-dose series 4–8 weeks apart if previously did not receive any varicella-containing vaccine, regardless of whether U.S.-born before 1980
- **HIV infection with CD4 count  $\geq 200$  cells/ $\mu$ L with no evidence of immunity:** Vaccination may be considered (2 doses, administered 3 months apart); VAR contraindicated in HIV infection with CD4 count  $< 200$  cells/ $\mu$ L
- **Severe immunocompromising conditions:** VAR contraindicated

## Zoster vaccination

## Routine vaccination

- **Age 50 years or older:** 2-dose series RZV (Shingrix) 2–6 months apart (minimum interval: 4 weeks; repeat dose if administered too soon), regardless of previous herpes zoster or history of ZVL (Zostavax) vaccination (administer RZV at least 2 months after ZVL)
- **Age 60 years or older:** 2-dose series RZV 2–6 months apart (minimum interval: 4 weeks; repeat if administered too soon) or 1 dose ZVL if not previously vaccinated. RZV preferred over ZVL (if previously received ZVL, administer RZV at least 2 months after ZVL)

## Special situations

- **Pregnancy:** ZVL contraindicated; consider delaying RZV until after pregnancy if RZV is otherwise indicated
- **Severe immunocompromising conditions (including HIV infection with CD4 count  $< 200$  cells/ $\mu$ L):** ZVL contraindicated; recommended use of RZV under review

## Pneumococcal vaccination

## Routine vaccination

- **Age 65 years or older** (immunocompetent—see [www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s\\_cid=mm6846a5\\_w](http://www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s_cid=mm6846a5_w)): 1 dose PPSV23
- If PPSV23 was administered prior to age 65 years, administer 1 dose PPSV23 at least 5 years after previous dose

## Shared clinical decision-making

- **Age 65 years and older** (immunocompetent): 1 dose PCV13 based on **shared clinical decision-making**
- If both PCV13 and PPSV23 are to be administered, PCV13 should be administered first
- PCV13 and PPSV23 should be administered at least 1 year apart
- PCV13 and PPSV23 should not be administered during the same visit

## Special situations

(see [www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s\\_cid=mm6846a5\\_w](http://www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm?s_cid=mm6846a5_w))

- **Age 19 through 64 years with chronic medical conditions (chronic heart [excluding hypertension], lung, or liver disease, diabetes), alcoholism, or cigarette smoking:** 1 dose PPSV23
- **Age 19 years or older with immunocompromising conditions (congenital or acquired immunodeficiency [including B- and T-lymphocyte deficiency, complement deficiencies, phagocytic disorders, HIV infection], chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, iatrogenic immunosuppression [e.g., drug or radiation therapy], solid organ transplant, multiple myeloma) or anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies):** 1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later, then another dose PPSV23 at least 5 years after previous PPSV23; at age 65 years or older, administer 1 dose PPSV23 at least 5 years after most recent PPSV23 (note: only 1 dose PPSV23 recommended at age 65 years or older)

- **Age 19 years or older with cerebrospinal fluid leak or cochlear implant:** 1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later; at age 65 years or older, administer another dose PPSV23 at least 5 years after PPSV23 (note: only 1 dose PPSV23 recommended at age 65 years or older)

## Tetanus, diphtheria, and pertussis vaccination

## Routine vaccination

- **Previously did not receive Tdap at or after age 11 years:** 1 dose Tdap, then Td or Tdap every 10 years

## Special situations

- **Previously did not receive primary vaccination series for tetanus, diphtheria, or pertussis:** At least 1 dose Tdap followed by 1 dose Td or Tdap at least 4 weeks after Tdap and another dose Td or Tdap 6–12 months after last Td or Tdap (Tdap can be substituted for any Td dose, but preferred as first dose); Td or Tdap every 10 years thereafter
- **Pregnancy:** 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36
- For information on use of Td or Tdap as tetanus prophylaxis in wound management, see [www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm](http://www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm)

## Varicella vaccination

## Routine vaccination

- **No evidence of immunity to varicella:** 2-dose series 4–8 weeks apart if previously did not receive varicella-containing vaccine (VAR or MMRV [measles-mumps-rubella-varicella vaccine] for children); if previously received 1 dose varicella-containing vaccine, 1 dose at least 4 weeks after first dose
- Evidence of immunity: U.S.-born before 1980 (except for pregnant women and health care personnel [see below]), documentation of 2 doses varicella-containing vaccine at least 4 weeks apart, diagnosis or verification of history of varicella or herpes zoster by a health care provider, laboratory evidence of immunity or disease

## Special situations

- **Pregnancy with no evidence of immunity to varicella:** VAR contraindicated during pregnancy; after pregnancy (before discharge from health care facility) 1 dose if previously received 1 dose varicella-containing vaccine or dose 1 of 2-dose series (dose 2: 4–8 weeks later) if previously did not receive any varicella-containing vaccine

## Td or Tdap may be used for decennial booster

- weeks apart if previously did not receive any varicella-containing vaccine, regardless of whether U.S.-born before 1980
- **HIV infection with CD4 count  $\geq 200$  cells/ $\mu$ L with no evidence of immunity:** Vaccination may be considered (2 doses, administered 3 months apart); VAR contraindicated in HIV infection with CD4 count  $< 200$  cells/ $\mu$ L
- **Severe immunocompromising conditions:** VAR contraindicated

## Zoster vaccination

## Routine vaccination

- **Age 50 years or older:** 2-dose series RZV (Shingrix) 2–6 months apart (minimum interval: 4 weeks; repeat dose if administered too soon), regardless of previous herpes zoster or history of ZVL (Zostavax) vaccination (administer RZV at least 2 months after ZVL)
- **Age 60 years or older:** 2-dose series RZV 2–6 months apart (minimum interval: 4 weeks; repeat if administered too soon) or 1 dose ZVL if not previously vaccinated. RZV preferred over ZVL (if previously received ZVL, administer RZV at least 2 months after ZVL)

## Special situations

- **Pregnancy:** ZVL contraindicated; consider delaying RZV until after pregnancy if RZV is otherwise indicated
- **Severe immunocompromising conditions (including HIV infection with CD4 count  $< 200$  cells/ $\mu$ L):** ZVL contraindicated; recommended use of RZV under review

# Adult Immunization Work Group

## ACIP Members

Paul Hunter (Chair)

Kevin Ault

## *Ex Officio* Members

## Consultants

Kathy Harriman (CA DOH)

Diane Peterson (IAC)

LJ Tan (IAC)

Carolyn Bridges (IAC)

Maria Lanzi (VA)

## CDC Staff

Mark Freedman (CDC Lead)

## Liaison Representatives

John Epling (AAFP)

Sandra Fryhofer (AMA, ACP)

Robert Hopkins (ACP)

Molly Howell (AIM)

Laura Pinkston Koenigs (SAHM)

Maria Lanzi (AANP)

Marie-Michèle Léger (AAPA)

Susan Lett (CSTE)

Chad Rittle (ANA)

William Schaffner (NFID)

Ken Schmader (AGS)

Rhoda Sperling (ACOG)

David Weber (SHEA)